131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinistat
Status:
Active, not recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
This study will compare three treatment regimens containing metaiodobenzylguanidine (MIBG)
and compare their effects on tumor response and associated side effects, to determine if one
therapy is better than the other for people diagnosed with relapsed or persistent
neuroblastoma.
Phase:
Phase 2
Details
Lead Sponsor:
New Approaches to Neuroblastoma Therapy Consortium